A randomized phase III study of oxaliplatin based chemotherapy versus combination chemotherapy of TS-1,irinotecan and bevacizumab as first line therapy for unresectable or recurrent colorectal cancer
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2623247
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: arm A-1:mFOLFOX6+Bevacizumab
Bevacizumab 5mg/kg/bi-week
L-OHP 85mg/m2/bi-week
l-LV 200mg/m2/bi-week
5-FU/bolus 400mg/m2/bi-week
5-FU/infusional 2,400mg/m2/bi-week
arm A-2: CapeOX+Bevacizumab
Bevacizumab 7.5mg/kg/tri-week
L-OHP 130mg/m2/tri-week
Capecitabine 1200-2100mg/twice/day(day 1-15)
arm B-1:TS-1/CPT-11+Bevacizumab(SIRB)
Bevacizumab 7.5mg/kg/tri-week
CPT-11 150mg/m2/tri-week
S-1 40-60mg/twice/day(day1-15)/tri-week
arm B-2:TS-1/CPT-11+Bevacizumab(IRIS/BV)
Bevacizumab 5mg/kg/(day1and15)/4-weeks
CPT-11 100mg/m2/(day1and15)/4-weeks
S-1 40-60mg/twice/day(day1-15)/4weeks
Primary outcome(s): Progression free survival(PFS)
Study Design: Parallel Randomized
创建时间：
2012-06-15
